This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.

This session presents a qualitative exploration of women's experiences with cardiovascular disease, highlighting unique challenges throughout their care pathway from diagnosis to rehabilitation. It shares robust patient experience data and offers recommendations aimed at improving cardiovascular care tailored to women’s specific needs.

This session focuses on specific percutaneous coronary intervention strategies for spontaneous coronary artery dissection (SCAD) and related coronary anomalies. It covers clinical and therapeutic aspects of adult coronary aneurysms, woven coronary anomalies, innovative stent optimization techniques, microvascular dysfunction in takotsubo syndrome, and real-world management of SCAD...

Examine recent advances in coronary disease treatment focusing on drug-eluting stents versus drug-coated balloon strategies. This session presents real-world data on lesion preparation, sex-specific outcomes, physiological disease patterns, and procedural factors influencing PCI success.

Elad Asher reviews the EROSION III trial, presented by Haibo Jia, which studied whether OCT guidance compared with angiographic guidance only is associated with lower stent rate implantation during pPCI in STEMI patients with non-obstructive stenosis.

Pierre Deharo and Giuseppe Di Gioia provide their take on this analysis of the 5 years incidence, outcomes and predictors of hemodynamic SVD in patients undergoing TAVI and surgery from the Corevalve US Pivotal and SURTAVI trials.

Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.

It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...

Ali Nazmi Calik provides a summary and key take-aways and infographics of 9 major trials of interest to interventional cardiologists presented at ACC.21

Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...

Nicola Ryan provides her take on the 10-year follow-up of the HOST-EXAM, which was presented by Hyo-Soo Kim at ACC.26 in New Orleans.